DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European Guidelines

This study has been completed.

First Received on October 5, 2005. Last Updated on November 18, 2010 History of Changes

Sponsor:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00233649

Purpose

The purpose of this study is to determine in DM II patients the efficacy of Crestor in obtaining the new European LDL cholesterol guidelines.

Condition	Phase
Diabetes Mellitus Type 2 Crestor, Rosuvastatin LDL Cholesterol Observational	Phase IV

Study Type:	Observational
Study Design:	Time Perspective: Prospective
Official Title:	DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European Guidelines

Resource links provided by NLM:

MedlinePlus related topics: Cholesterol Diabetes Diabetes Type 2

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Estimated Enrollment:	2500
Study Start Date:	May 2004

Eligibility

Study Population

Diabetes Mellitus Type 2

Criteria

Inclusion Criteria:

Diabetes Mellitus Type 2, LDL-C > 2,5 mmol/l, no cholesterol lowering medication used last 3 months, starts with Crestor 10 mg, permission to use patient data by AZ

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00233649

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:

Astra Zeneca

AstraZeneca

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00233649 History of Changes
Other Study ID Numbers:	NL401017
Study First Received:	October 5, 2005
Last Updated:	November 18, 2010
Health Authority:	European Union: European Medicines Agency

Additional relevant MeSH terms:

Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on February 09, 2012